Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Asia Medical and Agricultural Laboratory and Research Center PCL Liabilities-to-Assets Related Terms
Asia Medical and Agricultural Laboratory and Research Center PCL Liabilities-to-Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Medical and Agricultural Laboratory and Research Center PCL Liabilities-to-Assets Chart
Asia Medical and Agricultural Laboratory and Research Center PCL Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asia Medical and Agricultural Laboratory and Research Center PCL Liabilities-to-Assets vs Hardware Industry
Asia Medical and Agricultural Laboratory and Research Center PCL Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) has a Liabilities-to-Assets of 0.20 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL and its competitors.
Is Asia Medical and Agricultural Laboratory and Research Center PCL's Liabilities-to-Assets too high?
Asia Medical and Agricultural Laboratory and Research Center PCL's current Liabilities-to-Assets is 0.20. Overall, Asia Medical and Agricultural Laboratory and Research Center PCL has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asia Medical and Agricultural Laboratory and Research Center PCL's Liabilities-to-Assets compare to GRMN and COHR?
Asia Medical and Agricultural Laboratory and Research Center PCL's Liabilities-to-Assets of 0.20 can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Hardware company?
A good Liabilities-to-Assets depends on the Hardware industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL and its competitors. Asia Medical and Agricultural Laboratory and Research Center PCL's current Liabilities-to-Assets is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asia Medical and Agricultural Laboratory and Research Center PCL stock overvalued right now?
Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) is currently considered Modestly Overvalued. The stock's GF Value™ is ฿2.37, compared to a current price of ฿3.02 — trading 27.4% above its estimated fair value. The current Liabilities-to-Assets is 0.20. Asia Medical and Agricultural Laboratory and Research Center PCL's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC), the current Liabilities-to-Assets is 0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) Overvalued in 2026?
Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL stock appears to be overvalued.
The current stock price of ฿3.02 is trading 27.4% above its estimated GF Value™ of ฿2.37.
GuruFocus considers Asia Medical and Agricultural Laboratory and Research Center PCL to be Modestly Overvalued.
Key valuation signals for BKK:AMARC:
Liabilities-to-Assets: 0.20
GF Value™: ฿2.37 vs. price of ฿3.02 (27.4% above fair value)
No single metric tells the full story. See the BKK:AMARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asia Medical and Agricultural Laboratory and Research Center PCL is engaged in providing comprehensive scientific services for the agriculture, food, pharmaceutical and environment sectors including testing, calibration, inspection and certification according to international quality standards. The company geographically operates only in Thailand.
79GF Score
Get the complete analysis for BKK:AMARC
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:AMARC has been successfully added to your 
